S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:MRTX

Mirati Therapeutics - MRTX Stock Forecast, Price & News

$52.69
-0.72 (-1.35%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$49.39
$53.47
50-Day Range
$39.81
$98.62
52-Week Range
$32.96
$124.81
Volume
1.53 million shs
Average Volume
1.27 million shs
Market Capitalization
$3.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$81.47

Mirati Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
54.6% Upside
$81.47 Price Target
Short Interest
Bearish
18.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.68
Upright™ Environmental Score
News Sentiment
0.31mentions of Mirati Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$8.47 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

521st out of 1,053 stocks

Pharmaceutical Preparations Industry

264th out of 519 stocks


MRTX stock logo

About Mirati Therapeutics (NASDAQ:MRTX) Stock

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Mirati Drops on Acceptance of Cancer Drug
Why Mirati Therapeutics Shares Are Nosediving
Why Shares of Mirati Therapeutics Fell Wednesday
SVB Securities Reaffirms Their Buy Rating on Mirati Therapeutics (MRTX)
Why Shares of Mirati Therapeutics Fell Tuesday
Mirati Therapeutics: Poised For Takeoff
See More Headlines
Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Company Calendar

Last Earnings
11/08/2022
Today
2/01/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRTX
Fax
N/A
Employees
413
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$81.47
High Stock Price Forecast
$188.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+54.6%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
14 Analysts

Profitability

Net Income
$-581,780,000.00
Net Margins
-6,253.81%
Pretax Margin
-6,251.66%

Debt

Sales & Book Value

Annual Sales
$72.09 million
Book Value
$25.24 per share

Miscellaneous

Free Float
55,589,000
Market Cap
$3.03 billion
Optionable
Optionable
Beta
1.00

Key Executives

  • Mr. David D. Meek (Age 60)
    CEO & Director
    Comp: $974.53k
  • Dr. Charles M. Baum M.D.Dr. Charles M. Baum M.D. (Age 65)
    Ph.D., Founder, Pres, Head of R&D and Director
    Comp: $1.11M
  • Dr. James G. Christensen Ph.D. (Age 55)
    Exec. VP & Chief Scientific Officer
    Comp: $784.42k
  • Mr. Benjamin J. Hickey M.B.A.Mr. Benjamin J. Hickey M.B.A. (Age 48)
    Chief Commercial Officer
    Comp: $769.03k
  • Ms. Laurie D. Stelzer (Age 55)
    Chief Financial Officer
  • Ms. Reena R. Desai
    Chief Legal Officer & Corp. Sec.
  • Mr. Michael E. Paolucci (Age 63)
    Chief People Officer
  • Dr. Kelly Covello Ph.D.
    VP & Head of Medical Affairs
  • Mr. Ryan Asay
    VP & Head of Corp. Affairs
  • Dr. Alan Bart Sandler M.D. (Age 66)
    Exec. VP & Chief Medical Officer













MRTX Stock - Frequently Asked Questions

Should I buy or sell Mirati Therapeutics stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRTX shares.
View MRTX analyst ratings
or view top-rated stocks.

What is Mirati Therapeutics' stock price forecast for 2023?

14 Wall Street research analysts have issued 1-year price objectives for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $50.00 to $188.00. On average, they anticipate the company's stock price to reach $81.47 in the next year. This suggests a possible upside of 54.6% from the stock's current price.
View analysts price targets for MRTX
or view top-rated stocks among Wall Street analysts.

How have MRTX shares performed in 2023?

Mirati Therapeutics' stock was trading at $45.31 on January 1st, 2023. Since then, MRTX shares have increased by 16.3% and is now trading at $52.69.
View the best growth stocks for 2023 here
.

When is Mirati Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our MRTX earnings forecast
.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) issued its quarterly earnings data on Tuesday, November, 8th. The biotechnology company reported ($3.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.46) by $0.37. The biotechnology company had revenue of $5.43 million for the quarter, compared to the consensus estimate of $4.72 million. Mirati Therapeutics had a negative net margin of 6,253.81% and a negative trailing twelve-month return on equity of 60.40%.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include National Bank of Canada FI (0.64%), International Biotechnology Trust PLC (0.42%), Allspring Global Investments Holdings LLC (0.41%), New York State Common Retirement Fund (0.40%), Assenagon Asset Management S.A. (0.29%) and State of New Jersey Common Pension Fund D (0.05%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, David D Meek, Henry J Fuchs, Isan Chen, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends
.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $52.69.

How much money does Mirati Therapeutics make?

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $3.03 billion and generates $72.09 million in revenue each year. The biotechnology company earns $-581,780,000.00 in net income (profit) each year or ($13.39) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

The company employs 413 workers across the globe.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.

This page (NASDAQ:MRTX) was last updated on 2/2/2023 by MarketBeat.com Staff